Lung Cancer
The firm is preparing for a trial to show the efficacy of its CyPath Lung test and support a submission to the US Food and Drug Administration for marketing clearance.
Agilent Technologies Gains Expanded IVDR Certification for PD-L1 CDx
The test has been certified for use in the EU to help guide the treatment of early-stage non-small cell lung cancer and previously untreated advanced melanoma.
Biodesix Q4 Revenues up 39 Percent
The firm's improved financial results reflected significant growth in its lung cancer testing business, which includes a nodule risk test and a genomic test for therapy selection.
The firm is developing a protein-based lung cancer screening test that also utilizes machine learning.
The retrospective results suggest that the test's sensitivity boost over other platforms can overcome the challenge of detecting ctDNA in adenocarcinomas.